Ultivue, a Cambridge, MA-based early stage life sciences tools company, completed a $5.15m Series A financing.
Backers included ARCH Venture Partners, Hansjoerg Wyss, and other private investors.
Based on DNA-PAINT and DNA-Exchange technologies developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University by Peng Yin, Ph.D., Core Faculty member at the Wyss Institute and Associate Professor of Systems Biology at Harvard Medical School, and Dr. Ralf Jungmann, a former Postdoctoral Fellow in Yin’s Wyss Institute lab, now Group Leader at Max Planck Institute of Biochemistry and Ludwig Maximilian University in Munich, Germany, Ultivue produces reagents that enable researchers to obtain microscopic images at a high resolution. The company’s products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use. Its patented technologies enable single molecule detection and visualization of a multitude of biomolecules, including proteins and nucleic acids.
Drs. Yin and Jungmann co-founded the company with David R. Walt, Ph.D., co-founder of Illumina and Quanterix, University Professor at Tufts University, Founding Director of Tufts Institute for Innovation, and a Howard Hughes Medical Institute Professor.
In addition to the Series A funding, Ultivue has received an exclusive license from Harvard University for the Wyss Institute’s DNA-PAINT and DNA-Exchange technologies and acquired the rights to other technology from California Institute of Technology.